Author: Bristogiannis, Sotirios; Swan, Dawn; Thachil, Jecko
Title: Thromboprophylaxis in COVID-19 – Rationale and considerations Cord-id: eb2uvdsa Document date: 2021_7_23
ID: eb2uvdsa
Snippet: The Corona Virus Disease-2019 (COVID-19) pandemic is associated with a very high incidence of thrombotic complications. The exact mechanisms for this excess risk for clots have not been elucidated although one of the often-quoted pathophysiological entity is immunothrombosis. Recognition of thrombotic complications early on in this pandemic led to an over-explosion of studies which looked at the benefits of anticoagulation to mitigate this risk. In this review, we examine the rationale for throm
Document: The Corona Virus Disease-2019 (COVID-19) pandemic is associated with a very high incidence of thrombotic complications. The exact mechanisms for this excess risk for clots have not been elucidated although one of the often-quoted pathophysiological entity is immunothrombosis. Recognition of thrombotic complications early on in this pandemic led to an over-explosion of studies which looked at the benefits of anticoagulation to mitigate this risk. In this review, we examine the rationale for thromboprophylaxis in COVID-19 with particular reference to dosing and discuss what may guide the decision-making process to consider anticoagulation. In addition, we explore the rationale for thrombosis prevention measures in special populations including outpatient setting, pregnant females, children, those with high body mass index and those on extracorporeal membrane oxygenation.
Search related documents:
Co phrase search for related documents- active bleeding and acute respiratory syndrome: 1, 2
- active bleeding and lmwh molecular weight heparin: 1, 2
- active bleeding and lmwh therapeutic dose: 1
- active bleeding and low lmwh molecular weight heparin: 1, 2
- active bleeding and low molecular weight heparin: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date